Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CHRS Coherus BioSciences Inc
- Stocks
- Healthcare
- NASDAQ: CHRS
Price (delayed)
$0.797
Market cap
$92.4M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.13
Enterprise value
$278.19M
Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients' lives and to deliver significant savings
Highlights
Coherus BioSciences's gross margin has surged by 54% YoY
The debt has declined by 44% year-on-year
The gross profit has grown by 34% YoY but it has contracted by 25% from the previous quarter
The equity has plunged by 124% YoY and by 39% from the previous quarter
The net income has plunged by 121% YoY
Key stats
What are the main financial stats of CHRS
Market
Valuations
Earnings
Shares outstanding
115.93M
Market cap
$92.4M
Enterprise value
$278.19M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.41
Revenue
$197.5M
Gross profit
$111.88M
Operating income
-$114.58M
Net income
-$130.94M
EBIT
-$112.75M
EBITDA
-$106.54M
Free cash flow
$500,000
Per share
Balance sheet
Liquidity
EPS
-$1.13
EPS diluted
-$1.09
Free cash flow per share
$0
Book value per share
-$1.58
Revenue per share
$1.7
TBVPS
$2.75
Total assets
$371.07M
Total liabilities
$554.54M
Debt
$268.2M
Equity
-$183.47M
Working capital
$55.13M
Debt to equity
-1.46
Current ratio
1.22
Quick ratio
0.57
Net debt/EBITDA
-1.74
Margins
Efficiency
Dividend
EBITDA margin
-53.9%
Gross margin
56.6%
Net margin
-66.3%
Operating margin
-58%
Return on assets
-26.2%
Return on equity
N/A
Return on invested capital
-41.2%
Return on capital employed
-97.2%
Return on sales
-57.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CHRS stock price
How has the Coherus BioSciences stock price performed over time
Intraday
1.92%
1 week
-0.26%
1 month
-27.55%
1 year
-55.22%
YTD
-42.25%
QTD
-1.24%
Financial performance
How have Coherus BioSciences's revenue and profit performed over time
Revenue
$197.5M
Gross profit
$111.88M
Operating income
-$114.58M
Net income
-$130.94M
Gross margin
56.6%
Net margin
-66.3%
The net margin has dropped by 154% year-on-year
The net income has plunged by 121% YoY
Coherus BioSciences's gross margin has surged by 54% YoY
The operating income has grown by 44% YoY but it has contracted by 2.6% from the previous quarter
Price vs fundamentals
How does CHRS's price correlate with its fundamentals
Growth
What is Coherus BioSciences's growth rate over time
Valuation
What is Coherus BioSciences stock price valuation
P/E
N/A
P/B
N/A
P/S
0.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.41
Coherus BioSciences's EPS has shrunk by 55% YoY
The equity has plunged by 124% YoY and by 39% from the previous quarter
The P/S is 79% below the 5-year quarterly average of 2.2 and 22% below the last 4 quarters average of 0.6
The revenue has declined by 26% since the previous quarter and by 13% year-on-year
Efficiency
How efficient is Coherus BioSciences business performance
The return on assets has dropped by 170% year-on-year
Dividends
What is CHRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CHRS.
Financial health
How did Coherus BioSciences financials performed over time
The total assets is 33% less than the total liabilities
The total assets has plunged by 51% YoY and by 17% from the previous quarter
Coherus BioSciences's quick ratio has decreased by 44% YoY and by 35% QoQ
The equity has plunged by 124% YoY and by 39% from the previous quarter
The debt to equity has soared by 75% YoY and by 28% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.